That’s the title of a implausible editorial from Olivença et al. (2024). Lots of people once they take a look at pharmaceutical costs assume they’re ‘too excessive’ or ‘too low’. However the query is, too excessive or too low relative to what? What are our targets in pharmaceutical pricing. The editorial clearly articulates the problem as one in every of a market design downside. I’ve heard one of many co-authors (Dr. Lou Garrison) make this remark a number of occasions at conferences, however it’s useful to see this written down in print.
Of observe is that the market exclusivity medicine take pleasure in covers simply the manufacture of a selected product; opponents might arrive with competitor remedies and an identical generic copies might arrive after market exclusivity ends.
The worth of this monopoly energy is restricted by market competitors and time. This results in a market framework that promotes medical innovation by providing doubtlessly massive however unsure returns for high-risk investments, whereas utilizing competitors to control costs within the later phases of the product lifecycle.
The article begins by arguing towards setting drug costs simply primarily based on analysis and growth (R&D) price:
[Cost plus pricing]…not solely fails to acknowledge riskiness of those investments and the irrelevance on this market design of the prices of any particular product, but in addition the difficulties in figuring out related failed merchandise and in measuring their prices. Moreover, this angle would fail to convey the true worth of novel medicines for sufferers and society, and thus stifle innovation by sending no indicators of worth to traders within the extremely dangerous area of drug growth.
The article argues towards value setting akin to these argued by Bernie Sanders amongst others:
Notably, Senator Bernie Sanders has not too long ago requested Novo Nordisk for the R&D prices of semaglutide, a remedy for weight problems. It’s crucial that we talk that utilizing R&D prices to find out pricing is flawed and as a substitute focus ought to be made on estimating the complete worth {that a} medication offers to sufferers, their households and society. The ‘blockbuster mannequin’…which depends on the revenues of profitable medicine to cowl the prices of the numerous failed makes an attempt, is usually misunderstood or ignored in discussions about drug pricing and regulation. After all, corporations can nonetheless make revenue on a ‘marginal’ product if the revenues cowl the marginal R&D price and prices of manufacturing and distribution; however an organization wants a number of merchandise averaging multiples of common R&D price to cowl the failed merchandise.
The determine under summarizes the blockbuster mannequin.
A really attention-grabbing and clearly articulated editorial all through. Learn the complete piece right here.
